Source link : https://www.newshealth.biz/health-news/hrqol-the-same-with-cdk4-6-inhibitors-in-1st-or-2nd-line/
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or second line of therapy, according to investigators in the SONIA trial. The health-related quality of life data come from a new analysis of a secondary endpoint of […]
Author : News Health
Publish date : 2024-12-20 07:45:27
Copyright for syndicated content belongs to the linked Source.